Houli Liu

Houli Liu

Auto-generated profile, based on publicly available information

Houli Liu

College of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei, 230012, China.

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
YZYang Zhang
Yang Zhang
CYChenchen Yang
Chenchen Yang
MZMingsheng zhang
Mingsheng zhang
HLHouli Liu
Houli Liu
CGChen Gong
Chen Gong
YLYong Li
Yong Li
Interleukin enhancer-binding factor 3 and HOXC8 co-activate cadherin 11 transcription to promote breast cancer cells proliferation and migration Interleukin enhancer-binding factor 3 and HOXC8 co-activate cadherin 11 transcription to promote breast cancer cells proliferation and migration

20 January 2026 in Materials Today Bio
Verified
Journal Article
Open access
ZOZhaorong Ouyang
Zhaorong Ouyang
SLSiyu Li
Siyu Li
AZAo Zhang
Ao Zhang
SYShu Ye
Shu Ye
WYWanqiu Ye
Wanqiu Ye
HLHouli Liu
Houli Liu
Ganoderma lucidum polysaccharide (GLP) holds considerable promise for tumor therapy, but its clinical application is limited by its poor tumor-targeting capability. Herein, we report the development of an immunoregulatory nano-bioconjugate formed by conjugating GLPs with low-pH culture medium reprogrammed CT26 tumor cell-derived extracellular vesicle (LTEV). Specifically, 4-carboxybenzeneboronic acid (CPBA), used as an intermediate coupling agent, is conjugated with the amino group of LTEV via its carboxyl group to obtain CPBA-LTEV. GLP is then covalently linked via boric ester linkages between its hydroxyl groups and the boronic acid groups of CPBA. After systemic administration, GLP@LTEV accumulates in homologous tumor tissues derived from the LTEV parent cells, remodeling the immunosuppressive tumor microenvironment (TME) by repolarizing M2-like macrophages towards the M1 phenotype, promoting dendritic cell (DC) maturation, activating cytotoxic T lymphocytes (CTLs), and inhibiting immunosuppressive regulatory T cells (Tregs). The synergism of tumor-targeting delivery and potent immunomodulatory effects in this combined manner therefore significantly inhibits subcutaneous tumor growth and lung metastasis with minimal side effects, providing a novel combination of polysaccharide and nanovesicle for robust tumor immunotherapy.

6 December 2024 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
HLHouli Liu
Houli Liu
ZOZhaorong Ouyang
Zhaorong Ouyang
SLSiyu Li
Siyu Li
Extracellular vesicles derived from classically activated M1 macrophages (M1 EVs) have shown great potential in both tumor treatment and drug delivery. M1 EVs inherit specific biological messengers from their parent cells and possess the capability to activate immune cells residing in close or distant tumor tissues for antitumor therapy. Moreover, M1 EVs are commonly used as an attractive drug delivery system due to their tumor-targeting ability, biocompatibility, and non-toxic. They can effectively encapsulate various therapeutic cargoes through specific methods such as electroporation, co-incubation, sonication, extrusion, transfection, or click chemistry reaction. In this review, we provide a comprehensive summary of the advancements in M1 EVs for tumor therapy, discussing their application prospects and existing problems.

20 June 2024 in ACS Applied Nano Materials
Verified
Journal Article
Closed access
SLSiyu Li
Siyu Li
ZOZhaorong Ouyang
Zhaorong Ouyang
MZMengjie Zhang
Mengjie Zhang
SGShuai Guo
Shuai Guo
BCBiao Cai
Biao Cai
HLHouli Liu
Houli Liu

2 June 2026 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
ZOZhaorong Ouyang
Zhaorong Ouyang
WYWanqiu Ye
Wanqiu Ye
GWGuolei Wen
Guolei Wen
SLSiyu Li
Siyu Li
TWTao Wei
Tao Wei
HLHouli Liu
Houli Liu

7 March 2026 in Journal of Molecular Histology
Verified
Journal Article
Closed access
PDF file
ZOZhaorong Ouyang
Zhaorong Ouyang
FLFei Liu
Fei Liu
QLQingyang Lu
Qingyang Lu
YWYuan Wang
Yuan Wang
BCBiao Cai
Biao Cai
BCBiao Cai
Biao Cai